Abivax S.A. - Understand $abvx stock

$ABVX Market Cap: $689.6 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

-$208.5M

TTM

Current Assets

$286.0M

Q4 2023

Current Liabilities

$70.04M

Q4 2023

Current Ratio

408.29%

Q4 2023

Total Assets

$327.1M

Q4 2023

Total Liabilities

$131.1M

Q4 2023

Book Value

$196.0M

Q4 2023

Cash

$18.11M

Q4 2023

P/E

-3.308

Nov 29, 2024 EST

Free Cash Flow

-$151.7M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$10.00K	$0.00
YoY Change									-100.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$10.00K	$0.00
Cost Of Revenue		$110.0K	$0.00	$1.000K	$16.00K	$68.00K	$16.00K	$46.00K	$345.0K	$1.980M
Gross Profit		-$110.0K	$0.00	-$1.000K	-$16.00K	-$68.00K	-$16.00K	-$46.00K	-$345.0K	-$1.970M
Gross Profit Margin										-19700.0%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Selling, General & Admin	$28.82M	$8.000M	$6.366M	$5.688M	$4.973M	$4.363M	$3.886M	$3.628M	$3.522M	$20.00K
YoY Change	260.26%	25.67%	11.92%	14.38%	13.98%	12.27%	7.11%	3.01%	17510.0%
% of Gross Profit
Research & Development	$103.2M	$48.70M	€47.78M
YoY Change	111.86%	1.92%
% of Gross Profit
Depreciation & Amortization	$707.0K	$485.0K	$156.0K	$66.00K	$80.00K	$71.00K	$93.00K	$75.00K	$136.0K	$50.00K
YoY Change	45.77%	210.9%	136.36%	-17.5%	12.68%	-23.66%	24.0%	-44.85%	172.0%
% of Gross Profit
Operating Expenses	$127.4M	$56.49M	$42.56M	$38.01M	$33.28M	$19.04M	$14.13M	$18.19M	$17.91M	$3.090M	$10.00K
YoY Change	125.48%	32.73%	11.98%	14.2%	74.79%	34.71%	-22.3%	1.56%	479.61%	30800.0%
Operating Profit		-$56.60M	-$42.56M	-$38.01M	-$33.30M	-$19.11M	-$14.15M	-$18.24M	-$18.26M	-$5.060M
YoY Change		32.99%	11.98%	14.15%	74.25%	35.04%	-22.41%	-0.1%	260.77%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Interest Expense	-$15.83M	-$3.800M	-$436.0K	-$741.0K	-$1.274M	-$326.0K	$116.0K	$300.0K	-$119.0K	-$70.00K
YoY Change	316.45%	771.56%	-41.16%	-41.84%	290.8%	-381.03%	-61.33%	-352.1%	70.0%
% of Operating Profit
Other Income/Expense, Net	-$4.539M	-$100.0K	-$2.690M	-$1.577M	-$392.0K	-$134.0K	-$39.00K	-$42.00K		-$130.0K
YoY Change	4439.0%	-96.28%	70.58%	302.3%	192.54%	243.59%	-7.14%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Pretax Income	-$147.7M	-$74.40M	-$45.56M	-$40.13M	-$34.89M	-$19.79M	-$13.91M	-$17.83M	-$18.79M	-$5.860M	-$10.00K
YoY Change	98.58%	63.3%	13.54%	15.0%	76.28%	42.25%	-21.95%	-5.13%	220.63%	58500.0%
Income Tax	$0.00	-$4.500M	-$4.204M	-$2.575M	-$4.257M	-$3.970M	-$2.692M	-$3.519M	-$2.834M	-$780.0K	$0.00
% Of Pretax Income
Net Earnings	-$147.7M	-$69.80M	-$41.36M	-$37.55M	-$30.63M	-$15.82M	-$11.22M	-$14.31M	-$15.95M	-$5.080M	-$10.00K
YoY Change	111.66%	68.77%	10.14%	22.58%	93.6%	40.99%	-21.56%	-10.32%	214.06%	50700.0%
Net Earnings / Revenue										-50800.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$3.43	-$4.16	-$2.47	-$2.63	-$2.52	-$1.56	-$1.14	-$1.48	-$1.65	-$0.73	$0.00

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Cash & Short-Term Investments	$261.1M	$26.95M	$60.70M	$29.30M	$9.771M	$13.00M	$17.03M	$22.99M	$39.13M	$2.920M	$40.00K
YoY Change	868.94%	-55.6%	107.16%	199.89%	-24.85%	-23.66%	-25.91%	-41.25%	1239.97%	7200.0%
Cash & Equivalents	$18.11M	$6.000K	$6.000K	$6.000K	$6.000K	$5.006M	$15.15M	$15.05M	$39.01M	$1.700M
Short-Term Investments	$9.186M
Other Short-Term Assets	$5.745M	$915.0K	$699.0K	$324.0K	$342.0K	$201.0K	$197.0K	$51.00K	$118.0K	$330.0K
YoY Change	527.87%	30.9%	115.74%	-5.26%	70.15%	2.03%	286.27%	-56.78%	-64.24%
Inventory		$12.19M	$4.000M
Prepaid Expenses
Receivables		$759.0K	$1.472M	$1.787M	$1.718M	$2.632M	$3.647M	$4.803M	$3.909M	$0.00
Other Receivables		$7.557M	$8.340M	$6.254M	$6.413M	$5.142M	$0.00	$0.00	$0.00	$2.390M
Total Short-Term Assets	$286.0M	$36.18M	$75.21M	$37.67M	$18.24M	$20.98M	$20.88M	$27.84M	$43.15M	$5.640M	$40.00K
YoY Change	690.39%	-51.89%	99.68%	106.46%	-13.03%	0.48%	-25.02%	-35.48%	665.14%	14000.0%
Property, Plant & Equipment	$878.0K	$1.592M	$93.00K	$100.0K	$134.0K	$151.0K	$202.0K	$191.0K	$171.0K	$230.0K
YoY Change	-44.85%	1611.83%	-7.0%	-25.37%	-11.26%	-25.25%	5.76%	11.7%	-25.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$12.87M	$11.71M	$2.962M	$1.428M	$1.259M	$915.0K	$731.0K	$560.0K	$933.0K	$90.00K
YoY Change	9.92%	295.27%	107.42%	13.42%	37.6%	25.17%	30.54%	-39.98%	936.67%
Other Assets	$2.319M	$1.037M		$1.000K	$1.000K		$1.000K	$0.00	$2.000K	$0.00	$0.00
YoY Change	123.63%			0.0%				-100.0%
Total Long-Term Assets	$41.09M	$39.36M	$35.15M	$33.63M	$33.48M	$33.07M	$32.94M	$32.76M	$33.11M	$32.33M	$0.00
YoY Change	4.39%	11.98%	4.53%	0.44%	1.25%	0.4%	0.56%	-1.08%	2.42%
Total Assets	$327.1M	$75.54M	$110.4M	$71.30M	$51.73M	$54.05M	$53.82M	$60.60M	$76.27M	$37.97M	$40.00K
YoY Change
Accounts Payable	$47.22M	$15.48M	$18.55M	$17.41M	$10.55M	$6.654M	$4.219M	$2.571M	$2.808M	$1.050M	$10.00K
YoY Change	205.14%	-16.58%	6.57%	65.08%	58.48%	57.72%	64.1%	-8.44%	167.43%	10400.0%
Accrued Expenses	$6.073M	$2.300M	$2.652M	$1.987M	$1.843M	$1.819M	$1.102M	$974.0K	$915.0K	$840.0K
YoY Change	164.04%	-13.27%	33.47%	7.81%	1.32%	65.06%	13.14%	6.45%	8.93%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$10.61M	$10.70M					$170.0K	$170.0K	$320.0K
YoY Change	-0.89%						0.0%	-46.88%
Total Short-Term Liabilities	$70.04M	$32.13M	$28.05M	$32.64M	$19.20M	$14.40M	$9.777M	$5.925M	$7.053M	$5.220M	$10.00K
YoY Change	117.98%	14.56%	-14.08%	69.98%	33.34%	47.3%	65.01%	-15.99%	35.11%	52100.0%
Long-Term Debt	$44.86M	$31.75M	$53.45M	$33.98M	$20.74M	$10.90M	$92.00K	$146.0K	$85.00K	$2.090M	$0.00
YoY Change	41.3%	-40.6%	57.27%	63.82%	90.3%	11747.83%	-36.99%	71.76%	-95.93%
Other Long-Term Liabilities	$16.15M	$4.477M	$98.00K	$9.000K	$6.000K	$2.000K	$30.00K	$17.00K	$371.0K	$0.00
YoY Change	260.78%	4468.37%	988.89%	50.0%	200.0%	-93.33%	76.47%	-95.42%
Total Long-Term Liabilities	$61.01M	$36.22M	$53.54M	$33.99M	$20.75M	$10.90M	$122.0K	$163.0K	$456.0K	$2.090M	$0.00
YoY Change	68.43%	-32.35%	57.52%	63.82%	90.32%	8836.07%	-25.15%	-64.25%	-78.18%
Total Liabilities	$131.1M	$68.36M	$81.59M	$66.63M	$39.95M	$25.30M	$9.899M	$6.088M	$7.509M	$7.310M	$10.00K
YoY Change	91.72%	-16.22%	22.45%	66.78%	57.89%	155.62%	62.6%	-18.92%	2.72%	73000.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $689.62 Million

About Abivax S.A.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 40 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Industry: Pharmaceutical Preparations Peers: